New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 16, 2012
10:07 EDTALKS, AMTD, AGN, CHMT, ETFC, SCHW, VAROn The Fly: Analysts Initiation Summary
Today's noteworthy initiations include: Allergan (AGN) initiated with a Buy at SunTrust...Varian Medical (VAR) initiated with a Buy at Benchmark Co. and with a Buy at SunTrust...E-Trade (ETFC) initiated with a Neutral at Compass Point...TD Ameritrade (AMTD) initiated with a Neutral at Compass Point...Charles Schwab (SCHW) initiated with a Neutral at Compass Point...Chemtura (CHMT) initiated with a Buy at KeyBanc...Alkermes (ALKS) initiated with a Buy at Mizuho.
News For AGN;VAR;ETFC;AMTD;SCHW;CHMT;ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 8, 2016
07:23 EDTETFCCredit Suisse to hold a forum
17th Annual Credit Suisse Financial Services Forum is being held in New York where on February 8, some of the companies will be hosting dinners, followed by company presentations on February 9-10.
06:26 EDTSCHWCharles Schwab to host conference call
Subscribe for More Information
February 5, 2016
15:03 EDTAGNCourt rules in favor of Supernus on two patents in suit with Actavis
The U.S. District Court for the District of New Jersey entered judgment against Actavis, now known as Allergan (AGN), and in favor of Supernus (SUPN) as to the '898 and '131 patents disputed in a lawsuit between the two companies. The court found against Supernus and in favor of Actavis as to the '600 patent, according to a court filing. The Patents-in-Suit relate to Supernus' Oxtellar XR drug indicated for the treatment of seizures. Shares of Supernus are up 29% in afternoon trading following the court ruling.
07:51 EDTALKSWoodford calls Alkermes, Prothena selloffs 'greatly overdone'
British businessman Neil Woodford's Woodford Investment Management said it added to Alkermes (ALKS) and Prothena (PRTA) positions at what it considers to be "extremely attractive valuation levels." In its January letter to investors, the fund says the recent share price moves "look greatly overdone." Woodford also sold its position in GlaxoSmithKline (GSK) and initiated a new stake in Theravance Biopharma (TBPH). The company "retains a valuable economic interest in the future commercial potential of the respiratory franchise being developed in partnership with GlaxoSmithKline," the fund wrote. It also has "some very interesting, albeit earlier-stage, assets in therapeutic areas such as chronic obstructive pulmonary disease, cardiovascular & renal disease," it added. Woodford made no mention of Northwest Biotherapeutics (NWBO) in the letter, a company he invested in last year. Woodford Investment Management, established in 2014, describes itself as the "the opportunity for Neil Woodford, one of the UK's most highly-regarded fund managers, to distil his 30 years of experience and learning into a business founded on his own principles." Reference Link
February 4, 2016
08:33 EDTAMTDTD Ameritrade to acquire assets of FA Insight
TD Ameritrade has agreed to acquire the research, benchmarking and consulting capabilities of FA Insight. The transaction is expected to be completed by the second quarter of 2016.
February 3, 2016
06:13 EDTAGNPfizer insists Allergan deal won't be thwarted by U.S. politicians, FT says
Pfizer (PFE) has insisted that its $160B acquisition of Allergan (AGN) will not be stifled by political opposition, amid criticism that the deal will cost the U.S. Treasury billions of dollars in future tax revenues, the Financial Times reports. Pfizer CEO Ian Read also reiterated his intention to postpone until 2018 a decision on whether to break of the combined entity into two or three smaller companies, but has said that he would be open to offers for its generics unit, the report says. Mylan (MYL) has been connected to a potential acquisition of Pfizer's generic drugs business after it failed in its attempt to buy Perrigo (PRGO) last year, the report says. Reference Link
February 2, 2016
10:59 EDTAGNPfizer CEO confident Allergan deal can close in second half
Subscribe for More Information
08:59 EDTALKSLeerink views doc checks as positive for ACADIA, Neurocrine
Subscribe for More Information
07:20 EDTSCHWSEC Equity Market Structure Advisory Committee to hold a meeting
Subscribe for More Information
06:54 EDTAGNPfizer expects combination with Allergan to occur in 2H16
Subscribe for More Information
February 1, 2016
13:25 EDTAGNEarnings Watch: Pfizer shares down approximately 12% since last earnings report
Pfizer (PFE) is scheduled to report fourth quarter earnings before the market open on Tuesday, February 2, with a conference call scheduled for 10:00 am ET. Pfizer, a biopharmaceutical company, discovers, develops, manufactures, and sells healthcare products worldwide. Its product portfolio includes medicines and vaccines, as well as various consumer healthcare products. EXPECTATIONS: Analysts are looking for earnings per share of 52c on revenue of $13.57B, according to First Call. The consensus range for EPS is 49c-54c on revenue of $13.08B-$13.99B. LAST QUARTER: After completing its Hospira acquisition in early September, Pfizer reported third quarter EPS of 60c, which beat consensus estimates of 51c, on revenue of $12.1B, which was also higher than consensus estimates of $11.56B. In Q3 Operational revenue growth in in developed markets was driven primarily by the performance of several key products, including Prevnar 13 in adults, Ibrance and Eliquis -- all products that are early in their life cycles as well as from Lyrica primarily in the U.S., and the inclusion of one month of legacy Hospira U.S. operations. In emerging markets, revenues increased 5% operationally, reflecting continued strong operational growth, primarily from the Innovative Products business. Operational revenue growth was partially offset primarily by the loss of exclusivity and associated generic competition for Celebrex in the U.S., Zyvox in the U.S. and Lyrica in certain developed Europe markets. With its Q3 earnings announcement the company raised its fiscal year 2015 earnings per share view to $2.16-$2.20 from $2.04-$2.10 against a raised revenue view of $47.5B-$48.5B from $46.5B-$47.5B. Commenting on the improved yearly view, the company CFO said "We raised our 2015 financial guidance for reported revenues and adjusted diluted EPS to reflect the strong performance to date of Pfizer-standalone, excluding legacy Hospira operations coupled with an improved business outlook for Pfizer-standalone for the remainder of the year.PFIZER-ALLERGAN DEAL. On November 23, Pfizer and Allergan (AGN) announced that their boards of directors have unanimously approved, and the companies have entered into, a definitive merger agreement under which Pfizer will combine with Allergan. Pfizer at the time said it anticipates the Allergan transaction will deliver more than $2B in operational synergies over the first three years after closing. Pfizer anticipates that the combined company will have a pro forma Adjusted Effective Tax Rate of approximately 17%-18% by the first full year after the closing of the transaction. The transaction is expected to be neutral to Pfizer's Adjusted Diluted EPS in 2017, modestly accretive beginning in calendar year 2018, more than 10% accretive in 2019 with high-teens percentage accretion in 2020. STREET RESEARCH: On December 1, Barclays analyst Geoff Meacham kept an Equal Weight rating on Pfizer after assuming coverage of the name. The analyst maintained a $34 price target for shares.On November 25, SunTrust upgraded Pfizer to Neutral and increased its price target to $37 from $34 on shares. Analyst John Boris said the Allergan deal makes strategic sense, providing much needed growth from earlier life cycle assets with limited therapeutic overlap. PRICE ACTION: Shares of Pfizer are lower by approximately 12% since its last earnings report on October 27. Pfizer shares are trading over 1% lower to $29.97 in afternoon trading ahead of Tuesday morning's earnings.
January 29, 2016
07:59 EDTALKSAlkermes management to meet with JPMorgan
Subscribe for More Information
07:38 EDTAGNAllergan's Phase III rapastinel receives Breakthrough Therapy desgination by FDA
Subscribe for More Information
07:11 EDTAGNAllergan enters into global agreement with AstraZeneca for ATM-AVI
Allergan announced that it has entered into a global agreement with AstraZeneca to develop and commercialize ATM-AVI, an investigational, fixed-dose antibiotic combining aztreonam and avibactam. Together, the two companies will evaluate the combination to treat serious infections caused by metallo betalactamase MBL-producing Gram-negative pathogens, a difficult-to-treat sub-type of carbapenem-resistant Enterobacteriaceae, or CRE, for which there are currently very limited treatments, thus presenting a new treatment option for patients with MBL-producing pathogens. Under the terms of the agreement, Allergan will maintain commercialization rights in the U.S. and Canada and AstraZeneca will maintain commercialization rights in all other countries.
January 28, 2016
10:13 EDTALKSOptions with decreasing implied volatility
Subscribe for More Information
January 27, 2016
16:06 EDTVARVarian Medical sees FY16 EPS $4.55-$4.65, consensus $4.47
Subscribe for More Information
16:05 EDTVARVarian Medical sees Q2 EPS $1.06-$1.10, consensus $1.12
Subscribe for More Information
16:04 EDTVARVarian Medical reports Q1 EPS 99c, consensus 94c
Reports Q1 revenue $757.1M, consensus $746.56M.
06:46 EDTSCHWFee prices on mutual funds, ETFs sliding towards zero, WSJ says
There is intense fee price competition occurring in the asset management sector as several fund firms, including BlackRock (BLK), Charles Schwab (SCHW), and others, cut fees on their passive products close to 0%, the Wall Street Journal reports. The competition is suppressing industry margins and building a greater impetus for firms to achieve scale, the report says. The slide in costs have been under way for years but is accelerating as the sector's largest companies are targeting increasingly cost-obsessed investors, the report says. Over 100 mutual funds and exchanged-traded funds currently cost $10 or less per $10,000 invested, up from 40 in 2010, the report says, citing Morningstar. Reference Link
January 26, 2016
10:06 EDTALKSOptions with decreasing implied volatility
Options with decreasing implied volatility: SRPT GNC ALKS CALM NFLX CREE FFIV COH ISRG IBM
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use